AIRLINK 59.74 Decreased By ▼ -0.46 (-0.76%)
BOP 6.27 Increased By ▲ 0.02 (0.32%)
CNERGY 4.39 Increased By ▲ 0.33 (8.13%)
DFML 15.91 Increased By ▲ 0.16 (1.02%)
DGKC 71.25 Increased By ▲ 3.00 (4.4%)
FCCL 18.44 Increased By ▲ 0.82 (4.65%)
FFBL 26.10 Increased By ▲ 0.60 (2.35%)
FFL 9.15 Increased By ▲ 0.06 (0.66%)
GGL 10.33 Increased By ▲ 0.48 (4.87%)
HBL 114.80 Decreased By ▼ -0.20 (-0.17%)
HUBC 111.86 Decreased By ▼ -0.14 (-0.13%)
HUMNL 6.65 Increased By ▲ 0.10 (1.53%)
KEL 4.79 Increased By ▲ 0.26 (5.74%)
KOSM 4.68 Increased By ▲ 0.16 (3.54%)
MLCF 38.89 Increased By ▲ 0.99 (2.61%)
OGDC 123.17 Increased By ▲ 2.62 (2.17%)
PAEL 21.92 Increased By ▲ 0.17 (0.78%)
PIAA 10.95 Increased By ▲ 0.05 (0.46%)
PIBTL 5.99 Decreased By ▼ -0.03 (-0.5%)
PPL 108.34 Increased By ▲ 1.54 (1.44%)
PRL 28.12 Increased By ▲ 0.77 (2.82%)
PTC 11.07 Increased By ▲ 0.52 (4.93%)
SEARL 51.55 Decreased By ▼ -0.45 (-0.87%)
SNGP 67.81 Increased By ▲ 0.91 (1.36%)
SSGC 11.56 Increased By ▲ 0.03 (0.26%)
TELE 8.07 Increased By ▲ 1.02 (14.47%)
TPLP 11.72 Increased By ▲ 0.16 (1.38%)
TRG 75.71 Decreased By ▼ -5.04 (-6.24%)
UNITY 22.75 Increased By ▲ 1.60 (7.57%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 6,545 Increased By 61.1 (0.94%)
BR30 22,298 Increased By 199.8 (0.9%)
KSE100 63,703 Increased By 484.4 (0.77%)
KSE30 21,508 Increased By 202.1 (0.95%)
Business & Finance

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

  • The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.
  • The company said it plans to publish data from its tests against the South African and U.K. variants on the website.
Published January 25, 2021

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

Moderna said on Monday it plans to start clinical trials of an altered booster version of its COVID-19 vaccine aimed at the South African variant after tests showed its authorised vaccine may produce a diminished antibody response.

It will also test an additional booster shot of its authorised vaccine in trials to see if it boosts antibody reaction against the South Africa variant. The current regimen is for two shots four weeks apart.

The company said in a press release that it was being cautious and that the two-dose regimen of the vaccine was still expected to be protective against the South African and other variants detected to date.

The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.

The company said it plans to publish data from its tests against the South African and U.K. variants on the website bioRxiv.

Comments

Comments are closed.